Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 387, Issue 8, pp 707–718

cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Review

DOI: 10.1007/s00210-014-0999-8

Cite this article as:
Hoffmann, L.S. & Chen, H.H. Naunyn-Schmiedeberg's Arch Pharmacol (2014) 387: 707. doi:10.1007/s00210-014-0999-8

Abstract

Essential physiological homeostatic processes such as vascular tone, fluid balance, cardiorenal function, and sensory processes are regulated by the second messenger cyclic guanosine 3′, 5′-monophosphate (cGMP). Dysregulation of cGMP-dependent pathways plays an important role in cardiovascular diseases such as hypertension, pulmonary hypertension, heart failure, or erectile dysfunction. Thus, the cGMP pathway consisting of the cGMP-generating guanylyl cyclases, protein kinases, and phosphodiesterases (PDE) has evolved to an important drug target and is the focus of a wide variety of research fields ranging from unraveling mechanisms on the molecular level to understanding the regulation of physiological and pathophysiological processes by cGMP. Based on the results from basic and preclinical research, therapeutic drugs have been developed which modulate the cGMP pathway and are investigated in clinical trials. Riociguat, a nitric oxide (NO)-independent soluble guanylyl cyclase stimulator; recombinant B-type natriuretic peptide (BNP); or recombinant atrial natriuretic peptide (ANP) and PDE5 inhibitors are cGMP-modulating drugs that are already available for the treatment of pulmonary hypertension, acute heart failure, and erectile dysfunction, respectively. The latest results from basic to clinical research on cGMP were presented on the 6th International Conference on cGMP in Erfurt, Germany, and are summarized in this article.

Keywords

cGMPSoluble guanylyl cyclaseParticulate guanylyl cyclaseNitric oxidesGC stimulatorCardiovascular diseases

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Institute of Pharmacology and Toxicology, Biomedical CenterUniversity of BonnBonnGermany
  2. 2.Division of Cardiovascular DiseasesMayo ClinicRochesterUSA